Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development
Open Access
- 2 June 2009
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 125 (9) , 2095-2103
Abstract
Bladder cancer develops through different pathways, provisionally entitled “papillary” and “invasive.” Carcinoma in situ (CIS) is thought to be the precursor of invasive bladder cancer. However, little is known about chromosomal alterations of these clinically important lesions, and the relationship between chromosomal alterations and the different pathways. We laser‐microdissected 12 CIS and 4 dysplasia samples concomitant to invasive bladder cancer. We determined genome‐wide chromosome copy number changes and loss of heterozygosity (LOH) using Mapping 10K SNP microarrays. We further examined 48 high‐risk non‐muscle‐invasive bladder cancers using SNP microarrays to reveal characteristic changes correlated with the CIS‐phenotype. DNA copy‐number changes were further validated using QPCR in 77 independent tumor samples. CIS was found to be chromosomal unstable in 8 of 12 cases. Characteristic chromosomal changes were copy number gains of chromosomes 5p, 6p22.3, 10p15.1 and losses/LOH of chromosome 5q and 13q13‐q14. Tumor samples with these alterations were significantly associated with CIS. Using FGFR3 mutations as markers of the opposing papillary phenotype, we found 5p gains and FGFR3 mutations mutually exclusive. No FGFR3 mutations were found in 23 CIS and dysplasia samples. Based on this, we classified high‐risk non‐muscle‐invasive bladder tumors according to FGFR3 mutations and chromosomal changes into papillary and CIS‐type tumors with high correlation to CIS status (p = 0.001). Furthermore, we found significant correlation to the results of molecular classifiers based on gene‐expression. We concluded that chromosomal changes may be used to characterize different pathways in bladder cancer development. © 2009 UICCKeywords
Funding Information
- Danish Cancer Research Foundation
- Danish Cancer Society
- John and Birte Meyer Foundation
This publication has 38 references indexed in Scilit:
- Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation StudyClinical Cancer Research, 2007
- Histological and proteomic analysis of reversible H-Ras V12G expression in transgenic mouse skinCarcinogenesis, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Gene Expression Profiling Reveals Reproducible Human Lung Adenocarcinoma Subtypes in Multiple Independent Patient CohortsJournal of Clinical Oncology, 2006
- Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?Carcinogenesis, 2005
- A Molecular Signature in Superficial Bladder Carcinoma Predicts Clinical OutcomeClinical Cancer Research, 2005
- Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes predictionHuman Molecular Genetics, 2003
- Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical OutcomeJournal of Clinical Oncology, 2003
- Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) TumorsThe American Journal of Pathology, 2001
- Urothelial Atypia Concomitant with Primary Bladder TumourScandinavian Journal of Urology and Nephrology, 1987